EP3632439B1 - Demenztherapeutikum, das pyrazolochinolinderivat und donepezil kombiniert - Google Patents

Demenztherapeutikum, das pyrazolochinolinderivat und donepezil kombiniert Download PDF

Info

Publication number
EP3632439B1
EP3632439B1 EP18810578.7A EP18810578A EP3632439B1 EP 3632439 B1 EP3632439 B1 EP 3632439B1 EP 18810578 A EP18810578 A EP 18810578A EP 3632439 B1 EP3632439 B1 EP 3632439B1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutically acceptable
acceptable salt
donepezil
disease
tetrahydrofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP18810578.7A
Other languages
English (en)
French (fr)
Other versions
EP3632439A1 (de
EP3632439A4 (de
Inventor
Mai Miyamoto
Sadaharu Kotani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of EP3632439A1 publication Critical patent/EP3632439A1/de
Publication of EP3632439A4 publication Critical patent/EP3632439A4/de
Application granted granted Critical
Publication of EP3632439B1 publication Critical patent/EP3632439B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to a therapeutic agent for dementia combining a pyrazoloquinoline derivative having phosphodiesterase 9 (PDE9) inhibitory action or a pharmaceutically acceptable salt thereof, and donepezil or a pharmaceutically acceptable salt thereof
  • PDE9 phosphodiesterase 9
  • Pyrazoloquinoline derivatives represented by formula (I) (hereunder referred to as “compound (I)”) have phosphodiesterase 9 (PDE9) inhibitory action, and are considered to have promising ameliorative effects on cognitive function in Alzheimer's disease (PTL 1).
  • Donepezil represented by formula (II) (hereunder referred to as “compound (II)”) has acetylcholine esterase-inhibitory action, and has been reported to exhibit an effect against Alzheimer's disease and Lewy body dementia (see NPLs 1, 2 and 3).
  • acetylcholine esterase inhibitors galantamine and rivastigmine and the NMDA receptor antagonist memantine have been approved as therapeutic agents for Alzheimer's disease.
  • Donepezil is indicated for mild to severe Alzheimer's disease, and has been reported to have, in addition to a cognitive function-ameliorating effect, also an effect against peripheral symptoms such as agitation, anxiety, apathy, delusion, depression, disinhibition, hallucination, irritability, aberrant motor behavior and apathy (BPSD: Behavioral and Psychological Symptoms of Dementia) (see NPLs 4 and 5).
  • Galantamine and rivastigmine are indicated for mild to moderate Alzheimer's disease (see NPLs 6 and 7).
  • Memantine has been reported to have efficacy for ameliorating cognitive function, and for BPSD (agitation, irritability, aggression and behavioral disorder) in moderate to severe Alzheimer's disease (see NPLs 8 and 9). Combined use of different acetylcholine esterase inhibitors is contraindicated, but any acetylcholine esterase inhibitor may be used in combination with memantine.
  • acetylcholine esterase inhibitors are recommended for the core symptoms of Alzheimer's disease, with one of donepezil, galantamine or rivastigmine being selected first, and then switching to another acetylcholine esterase inhibitor if a problem arises in terms of effect or tolerance. When the effect of the acetylcholine esterase inhibitor is inadequate or a problem arises in terms of tolerance, combination with memantine or switching to memantine may be considered.
  • Acetylcholine esterase inhibitors have been reported to have digestive system side-effects, and to aggravate Parkinson's symptoms (see NPL 10).
  • memantine may be selected if the patient has moderate to severe Alzheimer's disease, but at the current time no effective method of treatment exists for other patients.
  • the combined use of acetylcholine esterase inhibitors with memantine is possible in patients that experience inadequate effects, but opinions are divided since some reports have indicated an effect by their combined use (see NPL 11) while other reports have indicated no effect (see NPL 12).
  • the invention relates to the following ⁇ 1> to ⁇ 19.3>.
  • the present invention provides a therapeutic agent for Alzheimer's disease and Lewy body dementia, combining a pyrazoloquinoline derivative represented by formula (I) having PDE9 inhibitory action, or a pharmaceutically acceptable salt thereof, and donepezil having acetylcholine esterase inhibitory action, or a pharmaceutically acceptable salt thereof.
  • the therapeutic agent using this combination exhibits a more notable ameliorative effect on cognitive function in animal models compared to their uses alone, and it has potential for use as a therapeutic agent for Alzheimer's disease and Lewy body dementia.
  • the scope of the invention is defined by the claims.
  • the references to methods of treatment in the summary and detailed description of the invention in this description are to be interpreted as references to the compounds, pharmaceutical compositions and medicaments of the present invention for use in a method for treatment of the human (or animal) body by therapy.
  • a "pharmaceutically acceptable salt” as referred to throughout the present specification is not particularly limited as long as it is a salt formed with the compound of the invention, and specific examples include acid addition salts such as inorganic acid salts, organic acid salts or acidic amino acid salts.
  • the number of acid molecules per one molecule of the compound in a formed salt is not particularly limited as long as the salt is formed in an appropriate ratio.
  • the number of acid molecules per one molecule of the compound is about 0.1 to about 5; in another embodiment, the number of acid molecules per one molecule of the compound is about 0.5 to about 2; and in still another embodiment, the number of acid molecules per one molecule of the compound is about 0.5, about 1 or about 2.
  • an inorganic acid salt examples include hydrochloride, hydrobromide, sulfate, nitrate and phosphate
  • specific examples of an organic acid salt include acetate, succinate, fumarate, maleate, tartrate, citrate, lactate, stearate, benzoate, methanesulfonate, p-toluenesulfonate and benzenesulfonate.
  • an acidic amino acid salt examples include aspartate and glutamate.
  • the pharmaceutical composition of the invention can be produced by mixing a pharmaceutically acceptable additive with compound (I) or a pharmaceutically acceptable salt thereof, and/or compound (II) or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition of the invention can be produced by a known method, such as the method described in the General Rules for Preparations of the Japanese Pharmacopoeia, 16th Editi on.
  • the pharmaceutical composition of the invention can be appropriately administered to a patient according to the dosage form.
  • the dose of compound (I) or a pharmaceutically acceptable salt thereof and compound (II) or a pharmaceutically acceptable salt thereof according to the invention will vary depending on the severity of symptoms, the patient age, gender and body weight, the form of administration and type of salt, and the specific type of disease, and the like; but usually, in adult, about 30 ⁇ g to 10 g, in one embodiment 100 ⁇ g to 5 g, and in another embodiment 100 ⁇ g to 1 g is administered orally per day, in a single dose or in several divided doses; or about 30 ⁇ g to 1 g, in one embodiment 100 ⁇ g to 500 mg, and in another embodiment 100 ⁇ g to 300 mg is administered by injection per day, in a single dose or in several divided doses.
  • Compound (I) can be produced by the method described in PTL 1, for example.
  • the present inventors confirmed the combined effects of compound (I) and donepezil hydrochloride using the following animal model.
  • Acetylcholine nervous system disorder has been reported in Alzheimer's disease and Lewy body dementia ( Whitehouse et al., Science, 1982, vol.215, p.1237 , Shimada et al., Neurology, vol.73, p.273, 2009 , Tiraboschi et al., Neurology 54(2000) 407-411 , Perry et. al., NeuroReport, vol.5, pp.747-749(1994 )), and scopolamine-administered animals are utilizable as an animal model for Alzheimer's disease and Lewy body dementia.
  • Scopolamine is a muscarine receptor inhibitor which blocks acetylcholine nervous system transmission.
  • the acetylcholine nervous system is involved in memory and attention, and healthy humans or animals administered scopolamine exhibit dementia-like amnesia symptoms which are attenuated by drugs used for treatment of cognitive impairment in Alzheimer's disease and Lewy body dementia ( Snyder et al., Alzheimer's & Dementia 1(2005)126-135 , Sambeth et al., European Journal of Pharmacology, vol.572(2007) pp.151-159 ).
  • 6-week-old male Long Evans rats (Institute for Animal Reproduction) were subjected to the test.
  • a habituation process to the experimental procedure was carried out once per day for 2 days prior to the test.
  • a vehicle was administered to the rats, and then the rats were placed in an empty test apparatus (40 cm ⁇ 30 cm ⁇ 45 cm height) and allowed to explore for 3 minutes, and after then placed in a waiting chamber (13 cm ⁇ 30 cm ⁇ 45 cm height) for about 1 minute, they were returned to the empty test apparatus again and left for 5 minutes.
  • An acquisition trial (II) was carried out on the day of the test.
  • Compound (I) was orally administered 2 hours before T1.
  • Donepezil hydrochloride was orally administered 1 hour before T1.
  • Scopolamine (Wako Pure Chemical Industries, Ltd.) was subcutaneously administered 30 minutes before T1 at a dose of 0.7 mg/kg.
  • T1 the rats were habituated to the empty test apparatus for 3 minutes and then placed in the waiting chamber. After setting two identical objects in the test apparatus, the rats were returned into the test apparatus again and allowed to freely explore the two identical objects for 5 minutes. The rats were then returned into their rearing cages. After 2 hours, a retention trial (T2) was carried out The rats were placed in the empty test apparatus for 3 minutes for habituation, and were then transferred into the waiting chamber.
  • T1 object used in T1
  • T1 object not used in T1
  • the rats were again returned into the test apparatus and allowed to freely explore these objects for 3 minutes.
  • the objects were wiped with a wet wipe impregnated with ethanol after each experiment so as to leave no trace of odor.
  • the behaviors of the rats during T1 and T2 were recorded by a digital video camera, and the total exploration time for each object was manually measured using a stopwatch. Exploratory behavior was defined as the behavior in which the rat brings its nose within 2 cm of the object and directs its nose toward the object.
  • the percentage of exploration of the novel object in T2 is considered to be an index for amnesia, reflecting discrimination between the familiar object and the novel object
  • the percentage of exploration of the novel object was calculated by the following formula.
  • results were expressed as mean ⁇ standard error.
  • the difference between the normal control group untreated with scopolamine and the disease control group treated with scopolamine was analyzed by an unpaired t-test (significant difference: *).
  • the difference between the disease control group and the single drug-treated group was analyzed by Dunnett-type multiple comparison test (significant difference: #).
  • the difference between the combined treatment group and the single drug-treated group was analyzed by Dunnett-type multiple comparison test (significant difference: ).
  • a value of p ⁇ 0.05 was judged to be a statistically significant difference.
  • Statistical analysis was conducted using GraphPad Prism version 5.04 or 6.02. The results are shown in Tables 1 to 5.
  • the rats of the disease control group exhibited a significantly lower percentage of exploration of the novel object than the rats of the normal control group. This means that memory impairment was induced in the rats by scopolamine.
  • Compound (I) exhibited a significant ameliorative effect on the percentage of exploration of the novel object at 3.3 mg/kg (Table 2), but did not exhibit a significant effect at 1 mg/kg (Table 1).
  • Donepezil hydrochloride exhibited a significant ameliorative effect on the percentage of exploration of the novel object at 0.3 mg/kg (Table 4), but did not exhibit a significant effect at 0.03 mg/kg (Table 3).

Claims (16)

  1. Therapeutikum umfassend (S)-7-(2-Methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]chinolin-4(5H)-on, dargestellt durch Formel (I):
    Figure imgb0032
     oder ein pharmazeutisch akzeptables Salz davon, und Donepezil, dargestellt durch Formel (II):
    Figure imgb0033
     oder ein pharmazeutisch akzeptables Salz davon, zur kombinierten Verwendung bei der Behandlung der Alzheimer-Krankheit oder Lewy-Körper-Demenz.
  2. Therapeutikum zur Verwendung gemäß Anspruch 1, wobei das Donepezil oder ein pharmazeutisch akzeptables Salz davon, Donepezilhydrochlorid ist.
  3. Therapeutikum zur Verwendung gemäß Anspruch 1 oder 2, wobei das (S)-7-(2-Methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]chinolin-4(5H)-on oder ein pharmazeutisch akzeptables Salz davon, (S)-7-(2-Methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]chinolin-4(5H)-on-maleat ist.
  4. Therapeutikum zur Verwendung gemäß mindestens einem der Ansprüche 1 bis 3, wobei die Alzheimer-Krankheit eine leichte, mittelschwere oder schwere Alzheimer-Krankheit ist.
  5. Therapeutikum umfassend (S)-7-(2-Methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]chinolin-4(5H)-on, dargestellt durch Formel (I):
    Figure imgb0034
    oder ein pharmazeutisch akzeptables Salz davon, und Donepezil, dargestellt durch Formel (II):
    Figure imgb0035
    oder ein pharmazeutisch akzeptables Salz davon, zur Verwendung bei der Behandlung der Alzheimer-Krankheit oder Lewy-Körper-Demenz, wobei (S)-7-(2-Methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]chinolin-4(5H)-on oder ein pharmazeutisch akzeptables Salz davon und Donepezil oder ein pharmazeutisch akzeptables Salz davon gleichzeitig oder getrennt verabreicht werden.
  6. Therapeutikum zur Verwendung gemäß Anspruch 5, wobei das Donepezil oder pharmazeutisch akzeptable Salz davon Donepezilhydrochlorid ist.
  7. Therapeutikum zur Verwendung gemäß Anspruch 5 oder 6, wobei das (S)-7-(2-Methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]chinolin-4(5H)-on oder ein pharmazeutisch akzeptables Salz davon, (S)-7-(2-Methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]chinolin-4(5H)-on-maleat ist.
  8. Therapeutikum zur Verwendung gemäß mindestens einem der Ansprüche 5 bis 7, wobei die Alzheimer-Krankheit eine leichte, mittelschwere oder schwere Alzheimer-Krankheit ist.
  9. Therapeutikum umfassend (S)-7-(2-Methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]chinolin-4(5H)-on, dargestellt durch Formel (I):
    Figure imgb0036
     oder ein pharmazeutisch akzeptables Salz davon, und Donepezil, dargestellt durch Formel (II):
    Figure imgb0037
     oder ein pharmazeutisch akzeptables Salz davon, zur Verwendung bei der Behandlung der Alzheimer-Krankheit oder Lewy-Körper-Demenz.
  10. Therapeutikum zur Verwendung gemäß Anspruch 9, wobei das Donepezil oder pharmazeutisch akzeptable Salz davon Donepezilhydrochlorid ist.
  11. Therapeutikum zur Verwendung gemäß Anspruch 9 oder 10, wobei das (S)-7-(2-Methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]chinolin-4(5H)-on oder ein pharmazeutisch akzeptables Salz davon, (S)-7-(2-Methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]chinolin-4(5H)-on-maleat ist.
  12. Therapeutikum zur Verwendung gemäß mindestens einem der Ansprüche 9 bis 11, wobei die Alzheimer-Krankheit eine leichte, mittelschwere oder schwere Alzheimer-Krankheit ist.
  13. (S)-7-(2-Methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]chinolin-4(5H)-on, dargestellt durch Formel (I):
    Figure imgb0038
     oder ein pharmazeutisch akzeptables Salz davon, zur Verwendung bei der Behandlung der Alzheimer-Krankheit oder Lewy-Körper-Demenz, wobei (S)-7-(2-Methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]chinolin-4(5H)-on oder ein pharmazeutisch akzeptables Salz davon verwendet wird in Kombination mit Donepezil, dargestellt durch Formel (II):
    Figure imgb0039
     oder ein pharmazeutisch akzeptables Salz davon.
  14. Verbindung, dargestellt durch Formel (I), oder ein pharmazeutisch akzeptables Salz davon, zur Verwendung gemäß Anspruch 13, wobei das Donepezil oder ein pharmazeutisch akzeptables Salz davon Donepezilhydrochlroid ist.
  15. Verbindung, dargestellt durch Formel (I), oder ein pharmazeutisch akzeptables Salz davon zur Verwendung gemäß Anspruch 13 oder 14, wobei das (S)-7-(2-Methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]chinolin-4(5H)-on oder ein pharmazeutisch akzeptables Salz davon, (S)-7-(2-Methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]chinolin-4(5H)-on-maleat ist.
  16. Verbindung, dargestellt durch Formel (I), oder ein pharmazeutisch akzeptables Salz davon zur Verwendung gemäß mindestens einem der Ansprüche 13 bis 15, wobei die Alzheimer-Krankheit eine leichte, mittelschwere oder schwere Alzheimer-Krankheit ist.
EP18810578.7A 2017-06-01 2018-05-30 Demenztherapeutikum, das pyrazolochinolinderivat und donepezil kombiniert Active EP3632439B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762513692P 2017-06-01 2017-06-01
PCT/JP2018/020638 WO2018221545A1 (ja) 2017-06-01 2018-05-30 ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤

Publications (3)

Publication Number Publication Date
EP3632439A1 EP3632439A1 (de) 2020-04-08
EP3632439A4 EP3632439A4 (de) 2021-02-17
EP3632439B1 true EP3632439B1 (de) 2024-03-27

Family

ID=64455958

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18810578.7A Active EP3632439B1 (de) 2017-06-01 2018-05-30 Demenztherapeutikum, das pyrazolochinolinderivat und donepezil kombiniert

Country Status (12)

Country Link
US (1) US11833146B2 (de)
EP (1) EP3632439B1 (de)
JP (2) JP7079777B2 (de)
KR (1) KR102627787B1 (de)
CN (1) CN110603040B (de)
AU (1) AU2018276565A1 (de)
BR (1) BR112019023569A2 (de)
CA (1) CA3060030A1 (de)
IL (1) IL270395B (de)
RU (1) RU2019135834A (de)
SG (2) SG11201909595VA (de)
WO (1) WO2018221545A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102627790B1 (ko) 2017-06-01 2024-01-23 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체와 메만틴을 병용한 치매 치료제
WO2018221551A1 (ja) 2017-06-01 2018-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体を含有するレビー小体病治療剤
BR112019023557A2 (pt) 2017-06-01 2020-06-02 Eisai R&D Management Co., Ltd. Composição farmacêutica compreendendo inibidor de pde9
KR102271305B1 (ko) 2020-05-21 2021-06-30 주식회사 아리바이오 치매 예방 및 치료용 조성물
KR102272907B1 (ko) 2020-11-05 2021-07-05 주식회사 아리바이오 치매 예방 및 치료용 조성물
KR102272910B1 (ko) 2021-01-28 2021-07-06 주식회사 아리바이오 당뇨병을 동반한 치매 예방 및 치료용 조성물
KR20220140960A (ko) 2021-04-12 2022-10-19 주식회사 아리바이오 당뇨병을 동반한 치매 예방 및 치료용 조성물
KR20220146095A (ko) 2021-04-23 2022-11-01 주식회사 아리바이오 Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물
KR102311224B1 (ko) 2021-04-23 2021-10-13 주식회사 아리바이오 Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물
CA3235146A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2769980B1 (de) * 2011-10-07 2016-02-03 Eisai R&D Management Co., Ltd. Pyrazolochinolinderivat als pde9-inhibitoren

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05132484A (ja) 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc ピラゾロキノリン及びピラゾロナフチリジン誘導体
DK0760819T3 (da) 1994-05-24 2000-10-09 Hoffmann La Roche Tricykliske dicarbonylderivater
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
WO1998030243A1 (en) * 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
WO2004014910A1 (en) 2002-08-07 2004-02-19 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE102004004142A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
RU2426734C2 (ru) 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Пиразолопиридины и их аналоги
US20060035920A1 (en) 2004-05-28 2006-02-16 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
JP2006045118A (ja) 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd 新規ピラゾロキノロン誘導体
EP1925617B1 (de) 2005-09-15 2012-11-14 ASKA Pharmaceutical Co., Ltd. Heterozyklische verbindung, herstellungsverfahren sowie verwendung
CN101557826A (zh) 2006-12-13 2009-10-14 Aska制药株式会社 泌尿系统疾病的治疗药
CN101553491B (zh) 2006-12-13 2013-05-29 Aska制药株式会社 喹喔啉衍生物
MX2009011830A (es) 2007-05-11 2009-11-13 Pfizer Compuestos amino-heterociclicos.
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
AP2011005672A0 (en) 2008-09-08 2011-04-30 Boehringer Ingelheim Int Pyrazolopyrimidines and their use for the treatment of CNS disorders.
TWI404721B (zh) * 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
AU2010219598A1 (en) 2009-03-05 2011-09-22 Astellas Pharma Inc. Quinoxaline compounds
BRPI1011533A2 (pt) 2009-03-31 2016-03-29 Boehringer Ingelheim Int derivados de 1-heterocicil-1 5- diidro-pirazolo [3,4--d] pirimidin-4-ona e seu uso como moduladores de pde9a.
US8880976B2 (en) 2009-09-25 2014-11-04 Stmicroelectronics, Inc. Method and apparatus for encoding LBA information into the parity of a LDPC system
EP3053924A1 (de) 2010-08-12 2016-08-10 Boehringer Ingelheim International Gmbh 6-cycloalkyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-on-derivate und deren verwendung als pde9a-hemmer
RS54834B1 (sr) 2010-09-07 2016-10-31 Astellas Pharma Inc Jedinjenja pirazolokvinolina
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) * 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
JP2013051639A (ja) 2011-08-31 2013-03-14 Kyocera Document Solutions Inc 画像形成装置
JP6042060B2 (ja) 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
PT2573073E (pt) 2011-09-26 2015-02-05 Sanofi Sa Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica
WO2014163147A1 (ja) 2013-04-05 2014-10-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体の塩およびその結晶
BR112019023557A2 (pt) 2017-06-01 2020-06-02 Eisai R&D Management Co., Ltd. Composição farmacêutica compreendendo inibidor de pde9
WO2018221551A1 (ja) 2017-06-01 2018-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体を含有するレビー小体病治療剤
KR102627790B1 (ko) 2017-06-01 2024-01-23 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체와 메만틴을 병용한 치매 치료제
CN108563565B (zh) 2018-04-08 2021-12-17 中国人民解放军海军工程大学 飞行着陆引导系统可靠性定量分析模型建立方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2769980B1 (de) * 2011-10-07 2016-02-03 Eisai R&D Management Co., Ltd. Pyrazolochinolinderivat als pde9-inhibitoren

Also Published As

Publication number Publication date
CA3060030A1 (en) 2018-12-06
US11833146B2 (en) 2023-12-05
US20200129501A1 (en) 2020-04-30
IL270395B (en) 2022-08-01
CN110603040A (zh) 2019-12-20
CN110603040B (zh) 2023-02-28
JP7079777B2 (ja) 2022-06-02
WO2018221545A1 (ja) 2018-12-06
JP7288999B2 (ja) 2023-06-08
JP2022110143A (ja) 2022-07-28
JPWO2018221545A1 (ja) 2020-04-02
BR112019023569A2 (pt) 2020-06-02
SG10202113198TA (en) 2021-12-30
RU2019135834A (ru) 2021-07-13
AU2018276565A1 (en) 2019-11-07
KR102627787B1 (ko) 2024-01-23
RU2019135834A3 (de) 2021-10-15
EP3632439A1 (de) 2020-04-08
KR20200010224A (ko) 2020-01-30
EP3632439A4 (de) 2021-02-17
IL270395A (de) 2020-02-27
SG11201909595VA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
EP3632439B1 (de) Demenztherapeutikum, das pyrazolochinolinderivat und donepezil kombiniert
EP3632437B1 (de) Pyrazolochinolinderivat und memantin kombinierendes therapeutikum zur behandlung von demenz
EP3632438B1 (de) Therapeutikum gegen lewy-körper-demenz mit einem pyrazolochinolinderivat
RU2784428C2 (ru) Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и мемантина
JP7144052B2 (ja) 掻痒性皮膚疾患の予防又は治療薬
EP2340832A1 (de) Morphinan-6-one-Verbindungen zur Behandlung oder Prävention von neurodegenerativen Erkrankungen
JPH05507075A (ja) 不安緩解剤およびノオトロピック剤用のベンジルイミダゾール誘導体

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191025

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210120

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 43/00 20060101ALI20210114BHEP

Ipc: A61P 25/28 20060101ALI20210114BHEP

Ipc: A61K 31/4745 20060101AFI20210114BHEP

Ipc: A61K 31/445 20060101ALI20210114BHEP

Ipc: A61P 25/16 20060101ALI20210114BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230522

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230510

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20231110

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018067239

Country of ref document: DE